Darien, IL and Fullerton, CA - September 26, 2002 - Eprogen, Inc. today announced it has signed an exclusive licensing and OEM agreement for Beckman Coulter Inc., (NYSE: BEC) to become the exclusive distributor of ProteoSep^™, Eprogen's patented protein discovery chemistry and software platform. Designed to advance the field of proteomics, ProteoSep will be marketed worldwide with Beckman Coulter's liquid chromatographic instrumentation.

ProteoSep was developed to address the need for improved analytical techniques in high-resolution protein analysis and was recently named an R&D 100 Award winner as one of the most significant technologies to reach the commercial market in 2001. By integrating ProteoSep into an automated and standardized instrumentation solution, Beckman Coulter seeks to provide valuable and novel information to academic or industrial researchers in life science environments who are working on the separation and characterization of proteins.

"This partnership marks the beginning of our initiative in the field of proteomics," said George Bers, president of Beckman Coulter's life science division. He continued, "It is a key element in our systems biology strategy and paves the way for the development of a new system that will completely automate the process for 2-dimensional protein mapping."

"Working with a life science leader like Beckman Coulter affords us an excellent opportunity to build on the enthusiastic response that we have received for ProteoSep from those involved in proteomics-based research," said Bruce Grotefend, president and chief executive officer of Eprogen. "This agreement strongly supports our business goal of establishing ProteoSep technology as the proteomics platform of choice for those involved in screening potential new drug candidates and evaluating new approaches to disease therapy".

Eprogen will continue to develop and utilize the ProteoSep platform in support of its Protein/Drug Discovery Services business.

Beckman Coulter, Inc. is a global biomedical company, headquartered in Fullerton, California. The company develops and markets instruments, chemistries, software and supplies that simplify and automate laboratory processes throughout the biomedical testing continuum. Through pioneering medical research and drug discovery, specialty testing, and patient care diagnostics, Beckman Coulter supports all phases of the battle against disease. Annual sales for the company totaled $2 billion in 2001, with 62% of this amount generated by recurring revenue from supplies, test kits and services. For more information, visit www.beckmancoulter.com.

Eprogen is a life sciences company that was formed to develop and market novel protein discovery technology. The Company's initial offering is a new platform that is designed to aid researchers in the field of drug discovery and disease monitoring. The Company also offers protein discovery services to researchers worldwide. Eprogen is headquartered in Darien, Illinois. For more information, visit www.eprogen.com.

For more information, please contact:
Bruce Grotefend
President & CEO
Eprogen, Inc.
8205 South Cass Avenue, Suite 111, Darien, IL 60561
Phone: 630.963.1481
Fax: 630.963.6432
E-mail: bgrotefend@eprogen.com
Linda Ciccone	Jeanie Herbert
Beckman Coulter	Investor Relations
Phone: 714.773.6983	Beckman Coulter
lmciccone@beckman.com	Phone: 714.773.7620